Functionally sensitive and resistant populations of lymphoid cells from normal and mammary tumor bearing mice following treatment with cyclophosphamide

Diana M Lopez, R. D. Paul, A. U. Gadgil, W. Lichter

Research output: Contribution to journalArticle

Abstract

The responses of splenocytes from normal and mammary tumor bearing Balb/c mice were assessed following treatment with cyclophosphamide in several immune reactions which may be important correlates of antitumor immunity. Although this drug is in common use as a treatment of many neoplasias including breast cancer, its effects on the lymphoid cells responding to tumor antigens have not been clearly elucidated. Administration of 100 mg/kg body weight of the drug two days prior to testing severely suppressed the lymphoproliferative and cytotoxic responses elicited by tumor associated antigens in mammary tumor bearing mice. Likewise, blastogenic responses to B and T cell mitogens were severely impaired. In sharp contrast, an equivalent dose of cyclosphosphamide did not affect either antibody dependent cellular cytotoxicity (ADCC) or lectin-induced cytotoxicity. When 200 mg/kg body weight was administered, the levels of phytohemagglutinin (PHA)-induced cytotoxicity were greatly reduced in both normal and tumor bearers, however, ADCC remained unaffected. Flow cytometric studies of cell surface markers determined that both Thy 1.2 positive and more profoundly, surface immunoglobulin bearing cells were diminished by cyclophosphamide treatment. The results suggest that the lymphoid cells which respond to tumor associated antigens, in PHA-induced cytotoxicity and in ADCC have qualitatively and quantitatively different susceptibilities to cyclophosphamide. These observations may help explain the chemotherapeutic effectiveness of cyclophosphamide in spite of its immunosuppressive properties.

Original languageEnglish
Pages (from-to)227-234
Number of pages8
JournalAnticancer Research
Volume2
Issue number4
StatePublished - Dec 1 1982

Fingerprint

Vulnerable Populations
Cyclophosphamide
Neoplasm Antigens
Lymphocytes
Breast Neoplasms
Phytohemagglutinins
Antibodies
Body Weight
B-Cell Antigen Receptors
Therapeutics
Immunosuppressive Agents
Mitogens
Lectins
Pharmaceutical Preparations
Immunity
Neoplasms
B-Lymphocytes
T-Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Functionally sensitive and resistant populations of lymphoid cells from normal and mammary tumor bearing mice following treatment with cyclophosphamide. / Lopez, Diana M; Paul, R. D.; Gadgil, A. U.; Lichter, W.

In: Anticancer Research, Vol. 2, No. 4, 01.12.1982, p. 227-234.

Research output: Contribution to journalArticle

@article{1c304359b390424ca53288de6dba80a9,
title = "Functionally sensitive and resistant populations of lymphoid cells from normal and mammary tumor bearing mice following treatment with cyclophosphamide",
abstract = "The responses of splenocytes from normal and mammary tumor bearing Balb/c mice were assessed following treatment with cyclophosphamide in several immune reactions which may be important correlates of antitumor immunity. Although this drug is in common use as a treatment of many neoplasias including breast cancer, its effects on the lymphoid cells responding to tumor antigens have not been clearly elucidated. Administration of 100 mg/kg body weight of the drug two days prior to testing severely suppressed the lymphoproliferative and cytotoxic responses elicited by tumor associated antigens in mammary tumor bearing mice. Likewise, blastogenic responses to B and T cell mitogens were severely impaired. In sharp contrast, an equivalent dose of cyclosphosphamide did not affect either antibody dependent cellular cytotoxicity (ADCC) or lectin-induced cytotoxicity. When 200 mg/kg body weight was administered, the levels of phytohemagglutinin (PHA)-induced cytotoxicity were greatly reduced in both normal and tumor bearers, however, ADCC remained unaffected. Flow cytometric studies of cell surface markers determined that both Thy 1.2 positive and more profoundly, surface immunoglobulin bearing cells were diminished by cyclophosphamide treatment. The results suggest that the lymphoid cells which respond to tumor associated antigens, in PHA-induced cytotoxicity and in ADCC have qualitatively and quantitatively different susceptibilities to cyclophosphamide. These observations may help explain the chemotherapeutic effectiveness of cyclophosphamide in spite of its immunosuppressive properties.",
author = "Lopez, {Diana M} and Paul, {R. D.} and Gadgil, {A. U.} and W. Lichter",
year = "1982",
month = "12",
day = "1",
language = "English",
volume = "2",
pages = "227--234",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Functionally sensitive and resistant populations of lymphoid cells from normal and mammary tumor bearing mice following treatment with cyclophosphamide

AU - Lopez, Diana M

AU - Paul, R. D.

AU - Gadgil, A. U.

AU - Lichter, W.

PY - 1982/12/1

Y1 - 1982/12/1

N2 - The responses of splenocytes from normal and mammary tumor bearing Balb/c mice were assessed following treatment with cyclophosphamide in several immune reactions which may be important correlates of antitumor immunity. Although this drug is in common use as a treatment of many neoplasias including breast cancer, its effects on the lymphoid cells responding to tumor antigens have not been clearly elucidated. Administration of 100 mg/kg body weight of the drug two days prior to testing severely suppressed the lymphoproliferative and cytotoxic responses elicited by tumor associated antigens in mammary tumor bearing mice. Likewise, blastogenic responses to B and T cell mitogens were severely impaired. In sharp contrast, an equivalent dose of cyclosphosphamide did not affect either antibody dependent cellular cytotoxicity (ADCC) or lectin-induced cytotoxicity. When 200 mg/kg body weight was administered, the levels of phytohemagglutinin (PHA)-induced cytotoxicity were greatly reduced in both normal and tumor bearers, however, ADCC remained unaffected. Flow cytometric studies of cell surface markers determined that both Thy 1.2 positive and more profoundly, surface immunoglobulin bearing cells were diminished by cyclophosphamide treatment. The results suggest that the lymphoid cells which respond to tumor associated antigens, in PHA-induced cytotoxicity and in ADCC have qualitatively and quantitatively different susceptibilities to cyclophosphamide. These observations may help explain the chemotherapeutic effectiveness of cyclophosphamide in spite of its immunosuppressive properties.

AB - The responses of splenocytes from normal and mammary tumor bearing Balb/c mice were assessed following treatment with cyclophosphamide in several immune reactions which may be important correlates of antitumor immunity. Although this drug is in common use as a treatment of many neoplasias including breast cancer, its effects on the lymphoid cells responding to tumor antigens have not been clearly elucidated. Administration of 100 mg/kg body weight of the drug two days prior to testing severely suppressed the lymphoproliferative and cytotoxic responses elicited by tumor associated antigens in mammary tumor bearing mice. Likewise, blastogenic responses to B and T cell mitogens were severely impaired. In sharp contrast, an equivalent dose of cyclosphosphamide did not affect either antibody dependent cellular cytotoxicity (ADCC) or lectin-induced cytotoxicity. When 200 mg/kg body weight was administered, the levels of phytohemagglutinin (PHA)-induced cytotoxicity were greatly reduced in both normal and tumor bearers, however, ADCC remained unaffected. Flow cytometric studies of cell surface markers determined that both Thy 1.2 positive and more profoundly, surface immunoglobulin bearing cells were diminished by cyclophosphamide treatment. The results suggest that the lymphoid cells which respond to tumor associated antigens, in PHA-induced cytotoxicity and in ADCC have qualitatively and quantitatively different susceptibilities to cyclophosphamide. These observations may help explain the chemotherapeutic effectiveness of cyclophosphamide in spite of its immunosuppressive properties.

UR - http://www.scopus.com/inward/record.url?scp=0020402412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020402412&partnerID=8YFLogxK

M3 - Article

C2 - 7149652

AN - SCOPUS:0020402412

VL - 2

SP - 227

EP - 234

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -